Leonardo M Rodrigues

US Patent:

20210080466, Mar 18, 2021

Filed:

Jun 26, 2020

Appl. No.:

16/913775

Inventors:

- Framingham MA, US
- Bethesda MD, US
Rangaprasad Sarangarajan - Boylston MA, US
Viatcheslav R. Akmaev - Sudbury MA, US
Leonardo Rodrigues - Ashland MA, US
Lixia Zhang - Natick MA, US
Shiv Srivastava - Potomac MD, US
Albert Dobi - Rockville MD, US
Jennifer Cullen - Gaithersburg MD, US

International Classification:

G01N 33/574

Abstract:

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of prostate cancer. The invention also provides methods of treating prostate cancer by administering a biomarker or an agent that modulates a biomarker of prostate cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

US Patent:

20200292548, Sep 17, 2020

Filed:

Feb 6, 2020

Appl. No.:

16/783238

Inventors:

- Framingham MA, US
- Bethesda MD, US
Rangaprasad Sarangarajan - Boylston MA, US
Viatcheslav R. Akmaev - Sudbury MA, US
Leonardo Rodrigues - Ashland MA, US
Lixia Zhang - Natick MA, US
Eric Milliman - Natick MA, US
Shiv Srivastava - Potomac MD, US
Albert Dobi - Rockville MD, US
Jennifer Cullen - Gaithersburg MD, US

International Classification:

G01N 33/574

Abstract:

Methods for diagnosing the presence of BCR in prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of BCR. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.

US Patent:

20200185063, Jun 11, 2020

Filed:

Jun 5, 2017

Appl. No.:

16/307406

Inventors:

- Framingham MA, US
Viatcheslav R. Akmaev - Sudbury MA, US
Leonardo Rodrigues - Ashland MA, US
Gregory Mark Miller - Natick MA, US

International Classification:

G16B 50/30
G16B 20/00
G16H 50/50
G16H 50/70
G16B 25/10
G16B 40/00
G16B 45/00

Abstract:

Disclosed herein are methods and systems for identifying one or more potential biomarkers for a clinical outcome related to administration of an agent. The method includes processing molecular profile data for a plurality of subjects where the molecular profile data includes data obtained before, during and/or after administration of an agent to the plurality of subjects. The method also includes processing clinical records data for the subjects, where the clinical records data includes clinical outcome data, integrating the processed molecular profile data and the processed clinical records data for the subjects and storing in a database as merged data, selecting two or more subsets of the merged data using one or more criteria based on the clinical records data to generate two or more selected data sets, and analyzing one or more of the selected data sets to identify one or more potential biomarkers for a clinical outcome related to administration of the agent.

US Patent:

20180024132, Jan 25, 2018

Filed:

Jul 7, 2017

Appl. No.:

15/644095

Inventors:

- Nashville TN, US
- Bethesda MD, US
Rangaprasad Sarangarajan - Boylston MA, US
Viatcheslav R. Akmaev - Sudbury MA, US
Leonardo Rodrigues - Ashland MA, US
Yezhou Sun - Framingham MA, US
Shiv Srivastava - Potomac MD, US
Albert Dobi - Rockville MD, US

International Classification:

G01N 33/574
C12Q 1/68

Abstract:

Methods for diagnosing the presence of prostate cancer in a subject are provided, such methods including the detection of levels of a variety of biomarkers diagnostic of prostate cancer. The invention also provides methods of treating prostate cancer by administering a biomarker or an agent that modulates a biomarker of prostate cancer. Compositions in the form of kits and panels of reagents for detecting the biomarkers of the invention are also provided.